Bayer AG’s consumer health business continues to recover with allergy/cold and dermatology categories driving total sales up 2.6%, adjusted for foreign exchange and portfolio changes, to €5.46bn ($6bn) in 2019, the German firm reported on 27 February.
Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
